|
Accueil > Actualité
GenSight Biologics: Goldman Sachs falls below 5% threshold
(CercleFinance.com) - On August 27, Goldman Sachs Group declared to the AMF that it had fallen below the thresholds of 5% of the capital and voting rights in GenSight Biologics, as a result of an off-market sale of shares to which the trading exemption applies.
The US investment bank no longer holds any GenSight shares within the meaning of Article 223-13 I, 2° of the General Regulations. At the same time, Goldman Sachs International individually crossed downwards the same thresholds. Copyright (c) 2024 CercleFinance.com. All rights reserved. |
19/09/2024 17:10
Adyenen forte hausse, UBS reste à l'achat 19/09/2024 17:03 Targetnouveau directeur financier recruté chez PepsiCo 19/09/2024 16:51 Continentalprojet de centre logistique à Dallas 19/09/2024 16:40 MobileyeIntel exclut de céder ses parts, le titre grimpe 19/09/2024 16:33 Rolls-Roycesigne un contrat avec Netinera en Allemagne 19/09/2024 15:55 GenSight BiologicsArmistice Capital passe sous les 5% Tous les articles sociétés |
